Investors who bought Pacira BioSciences, Inc. Securities between August 2, 2023, and August 8, 2024, must act by March 14, 2025, if they wish to be considered as lead plaintiffs in a class action lawsuit. The lawsuit asserts that statements made by Pacira during the class period regarding patent protections for Exparel were inaccurate and deceptive. Allegedly, Pacira overstated the strength of its patent protections, potentially causing losses for investors. Those who acquired Pacira securities during this period could potentially receive compensation at no upfront cost through a contingency fee agreement.